Achmea Investment Management B.V. trimmed its stake in AbbVie Inc (NYSE:ABBV) by 5.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 114,553 shares of the company’s stock after selling 6,156 shares during the period. Achmea Investment Management B.V.’s holdings in AbbVie were worth $8,304,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABBV. MCF Advisors LLC grew its holdings in AbbVie by 15.3% during the 1st quarter. MCF Advisors LLC now owns 4,556 shares of the company’s stock worth $297,000 after acquiring an additional 606 shares during the period. Greatmark Investment Partners Inc. grew its holdings in AbbVie by 1.7% during the 1st quarter. Greatmark Investment Partners Inc. now owns 33,936 shares of the company’s stock worth $2,211,000 after acquiring an additional 560 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in AbbVie by 33.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 461,768 shares of the company’s stock worth $30,441,000 after acquiring an additional 115,550 shares during the period. Community Bank N.A. grew its holdings in AbbVie by 1.6% during the 1st quarter. Community Bank N.A. now owns 66,262 shares of the company’s stock worth $4,317,000 after acquiring an additional 1,015 shares during the period. Finally, Massmutual Trust Co. FSB ADV grew its holdings in AbbVie by 16.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 98,704 shares of the company’s stock worth $6,432,000 after acquiring an additional 14,194 shares during the period. Institutional investors and hedge funds own 69.32% of the company’s stock.

In related news, VP Robert A. Michael sold 6,699 shares of the firm’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $88.00, for a total value of $589,512.00. Following the transaction, the vice president now owns 10,007 shares of the company’s stock, valued at approximately $880,616. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the completion of the transaction, the chairman now directly owns 492,030 shares in the company, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. Insiders have sold a total of 414,335 shares of company stock worth $39,258,362 in the last three months. Insiders own 0.23% of the company’s stock.

A number of brokerages have weighed in on ABBV. Leerink Swann set a $106.00 price target on AbbVie and gave the stock a “buy” rating in a report on Tuesday, December 5th. UBS downgraded AbbVie from a “buy” rating to a “neutral” rating and increased their price target for the stock from $79.00 to $92.00 in a report on Monday, September 25th. SunTrust Banks reiterated a “buy” rating and set a $95.00 price target on shares of AbbVie in a report on Wednesday, September 13th. Argus increased their price target on AbbVie from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Finally, Jefferies Group reiterated a “buy” rating and set a $107.00 price target on shares of AbbVie in a report on Thursday, September 28th. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $97.96.

AbbVie Inc (ABBV) opened at $97.45 on Friday. The stock has a market cap of $153,736.20, a PE ratio of 18.14, a PEG ratio of 1.34 and a beta of 1.52. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 1 year low of $59.27 and a 1 year high of $98.87.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.21 EPS. research analysts forecast that AbbVie Inc will post 5.55 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is 62.29%.

TRADEMARK VIOLATION NOTICE: This report was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.watchlistnews.com/achmea-investment-management-b-v-sells-6156-shares-of-abbvie-inc-abbv/1767315.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.